Clinical reference Biomarker Directory
Back to directory

Homocysteine

Established

Homocysteine helps detect B12/folate deficiency, sometimes before classic markers become abnormal.

Also known as Homocysteine tHcy
In plain language

Homocysteine rises when the body lacks enough B12 or folate to process it properly, sometimes flagging a deficiency before other tests do. It was once hoped that lowering it with vitamins would reduce heart disease risk, but large studies showed this doesn't actually prevent heart attacks or strokes, even though it does lower the homocysteine number itself.

Biomarker & context

Homocysteine is an amino acid byproduct of methionine metabolism, requiring vitamin B12, folate, and B6 for proper clearance; elevated levels reflect deficiency in these vitamins or, less commonly, genetic enzyme defects in this pathway.

What it indicates

Elevated homocysteine supports vitamin B12 or folate deficiency, sometimes detecting deficiency before classic markers (low B12, macrocytic anemia) become abnormal; it has also been studied as an independent cardiovascular risk factor, though this association remains more debated than its role in vitamin deficiency diagnosis.

Diagnosis & clinical testing

Measured via immunoassay or HPLC/mass spectrometry; results can be affected by kidney function (elevated in reduced kidney function independent of vitamin status) and require careful interpretation alongside methylmalonic acid (a more B12-specific marker) when the cause of elevation is ambiguous.

Guiding treatment

Vitamin B12 and folate supplementation lowers homocysteine and treats the underlying deficiency; however, several large cardiovascular trials found that homocysteine-lowering therapy with B vitamins did not reduce cardiovascular events despite successfully lowering homocysteine levels, a notable disconnect between biomarker modification and actual clinical outcome that tempered enthusiasm for homocysteine as a treatment target.

Clinical significance

Large cardiovascular trials found homocysteine-lowering therapy doesn't reduce cardiovascular events despite lowering the biomarker itself.

References
  1. General hematology and cardiology reference literature on homocysteine in vitamin deficiency diagnosis and cardiovascular risk trials.